Eyegenex has recently gathered promising data on their drug candidate, CPP-P1, designed to fight the rising number of blindness cases in patients with glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). The widespread use of semaglutide (e.g., Ozempic) for weight loss has led to more cases of NAION. Both glaucoma and NAION cause vision loss by damaging the optic nerve cells.
In a recent publication, the authors shared results from detailed lab studies on animals and tissue samples, all demonstrating the significant potential of CPP-P1 to prevent blindness.
Key findings include:
Eyegenex thanks Ram Nagaraj, Dorota Stankowska, and the other authors for their important contributions to this research. Their work has paved the way for possible breakthroughs in preventing blindness in glaucoma and NAION.
Eyegenex
A San Diego Pharmaceutical Company. A Seed To Fruit Portfolio Company.
Copyright © 2023 Eyegenex - All Rights Reserved.